Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Omniscan (gadodiamide) for 3D Contrast-Enhanced MRA in Renal Artery Stenosis
2004-000953-46Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Oct 2004
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of gadodiamide in renal artery stenosis (RAS) (2 arms), sponsored by GE HealthCare. Primary endpoints: Sensitivity of 3D contrast-enhanced MRA for detecting main renal artery stenosis and Specificity of 3D contrast-enhanced MRA for detecting main renal artery stenosis. Started Oct 2004; status: completed.
02
Drugs
gadodiamide
03
Conditions
renal artery stenosis (RAS)
Beyond the preview
Go deeper on 2004-000953-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000953-46.